MedPath

The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Completed
Conditions
Hepatitis C Virus
Registration Number
NCT02581020
Lead Sponsor
AbbVie
Brief Summary

This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment of chronic hepatitis C.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
344
Inclusion Criteria
  • Participants treated in Study M12-536 or M13-004 with the 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow-up, regardless of SVR achievement.
  • Participants who agree to sign the informed consent
Exclusion Criteria
  • Participants treated with a direct-acting antiviral agent (DAA) immediately after Study M12-536 or M13-004.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hepatitis C virus ribonucleic acid (HCV RNA) levels60 months after completion of the 2D treatment in M12-536 or M13-004 study

HCV RNA levels in plasma

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Ombitasvir in Non-structural Viral Protein 5A (NS5A)For approximately 5 years
Number of participants with serious adverse events (SAEs)Up to 60 month after completion of the 2D treatment in M132-536 or M13-004 study

All serious adverse events will be monitored during the observation period.

Hepatitis C virus ribonucleic acid (HCV RNA) levels18, 24, 30, 36, 42, 48, 52 months after completion of the 2D treatment in M12-536 or M13-004 study

HCV RNA levels in plasma

Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Paritaprevir in Non-structural Viral Protein 3 (NS3)For approximately 5 years
Percentage of participants with hepatocellular carcinomaUp to 60 month after completion of the 2D treatment in M12-536 or M13-004

Trial Locations

Locations (53)

Kurume University Hospital /ID# 152123

🇯🇵

Kurume-shi, Fukuoka, Japan

Kawasaki Municipal Tama Hospit /ID# 153546

🇯🇵

Kawasaki, Japan

Hiroshima University Hospital /ID# 152232

🇯🇵

Hiroshima-shi, Hiroshima, Japan

Duplicate_Kanazawa University Hospital /ID# 152226

🇯🇵

Kanazawa-shi, Ishikawa, Japan

JP Red Cross Musashino Hosp /ID# 152175

🇯🇵

Tokyo, Japan

Kawasaki Hosp, Kawasaki Med /ID# 152180

🇯🇵

Okayama, Japan

Jichi Medical University Hospital /ID# 153018

🇯🇵

Shimotsuke-shi, Tochigi, Japan

Saitama Medical University Hospital /ID# 153544

🇯🇵

Iruma-gun, Saitama, Japan

Nagoya City University Hospital /ID# 157439

🇯🇵

Nagoya-shi, Aichi, Japan

Fukuoka University Hospital /ID# 155965

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Ogaki Municipal Hospital /ID# 158105

🇯🇵

Ogaki-shi, Gifu, Japan

Toyama Prefectural Central Hospital /ID# 164156

🇯🇵

Toyama-shi, Toyama, Japan

Kumamoto Shinto General Hospital /ID# 150061

🇯🇵

Kumamoto-shi, Kumamoto, Japan

Asakura Medical Association Ho /ID# 155963

🇯🇵

Asakura, Japan

Japanese Red Cross Osaka Hospital /ID# 155964

🇯🇵

Osaka-shi, Osaka, Japan

Fukuiken Saiseikai Hospital /ID# 162898

🇯🇵

Fukui, Japan

Nippon Med Chiba Hokusoh Hosp /ID# 164155

🇯🇵

Inzai, Japan

Hitachi General Hospital /ID# 160800

🇯🇵

Hitachi-shi, Ibaraki, Japan

Duplicate_Yokohama City University Medical Center /ID# 159474

🇯🇵

Yokohama-shi, Kanagawa, Japan

Kagoshima Uni Med and Dental /ID# 157438

🇯🇵

Kagoshima, Japan

Saiseikai Suita Hospital /ID# 153549

🇯🇵

Suita, Japan

Osaka Hospital /ID# 152177

🇯🇵

Osaka, Japan

Toranomon Hospital /ID# 152124

🇯🇵

Minato-ku, Tokyo, Japan

Kagawa University Hospital /ID# 153548

🇯🇵

Kita-gun, Kagawa, Japan

Yokohama City University Hospital /ID# 165252

🇯🇵

Yokohama-shi, Kanagawa, Japan

The University of Tokyo Hospital /ID# 158121

🇯🇵

Bunkyo-ku, Tokyo, Japan

Ehime Prefectural Central Hosp /ID# 158106

🇯🇵

Matsuyama, Japan

University of Yamanashi Hospital /ID# 153547

🇯🇵

Chuo-shi, Yamanashi, Japan

Japanese Red Cross Saitama Hos /ID# 166898

🇯🇵

Saitama, Japan

Oita University Hospital /ID# 165274

🇯🇵

Yufu-shi, Japan

Matsuyama Red Cross Hospital /ID# 152125

🇯🇵

Matsuyama-shi, Ehime, Japan

National Hospital Organization Kyushu Medical Center /ID# 161759

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Gunma University Hospital /ID# 158118

🇯🇵

Maebashi-shi, Gunma, Japan

National Hospital Organization Takasaki General Medical Center /ID# 152128

🇯🇵

Takasaki-shi, Gunma, Japan

Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital /ID# 152178

🇯🇵

Hiroshima-shi, Hiroshima, Japan

Obihiro kosei Hospital /ID# 157437

🇯🇵

Obihiro-shi, Hokkaido, Japan

Tokyo Med Uni Ibaraki Med Ctr /ID# 152127

🇯🇵

Inashiki, Japan

Gifu Municipal Hospital /ID# 152227

🇯🇵

Gifu, Japan

Okayama University Hospital /ID# 150060

🇯🇵

Okayama-shi, Okayama, Japan

Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 153019

🇯🇵

Sapporo-shi, Hokkaido, Japan

Osaka City General Hospital /ID# 152126

🇯🇵

Osaka-shi, Osaka, Japan

Saga University Hospital /ID# 161757

🇯🇵

Saga-shi, Saga, Japan

Dokkyo Medical University Hospital /ID# 152225

🇯🇵

Shimotsuga-gun, Tochigi, Japan

Yamaguchi University Hospital /ID# 166899

🇯🇵

Ube-shi, Yamaguchi, Japan

Gifu Prefectural Genl Med Ctr /ID# 154796

🇯🇵

Gifu, Japan

Toranomon Hospital Kajigaya /ID# 152129

🇯🇵

Kawasaki, Japan

Hamamatsu University Hospital /ID# 152176

🇯🇵

Hamamatsu-shi, Shizuoka, Japan

Toshiba General Hospital /ID# 152122

🇯🇵

Tokyo, Japan

Ikeda Municipal Hospital /ID# 150062

🇯🇵

Ikeda, Japan

Kagawa Prefectural Central Hos /ID# 152179

🇯🇵

Takamatsu, Japan

Nat Hosp Org Minami Wakayama /ID# 153550

🇯🇵

Tanabe, Japan

Juntendo University Hospital /ID# 153545

🇯🇵

Bunkyo-ku, Tokyo, Japan

Kitasato University Kitasato Institute Hospital /ID# 152145

🇯🇵

Minato-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath